导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.12% | 3898/4773 |
| 近一周 | -2.53% | 4001/5465 |
| 近一月 | -9.05% | 5153/5421 |
| 近一季 | -18.25% | 4716/5231 |
| 近半年 | -15.21% | 4058/4920 |
| 近一年 | -12.95% | 3589/4394 |
| 近两年 | 44.01% | 1725/2954 |
| 近三年 | 13.70% | 1670/2253 |
| 成立以来 | 80.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.30% 3118/4961 |
14.88% 1744/5312 |
- - |
- - |
| 2025 | 21.26% 2047/4813 |
-0.63% 2329/3635 |
-1.07% 3104/4076 |
30.85% 1154/4524 |
-5.73% 3608/4813 |
| 2024 | 10.84% 1369/3463 |
-4.90% 1795/2808 |
-5.13% 1657/3014 |
25.01% 317/3129 |
-1.73% 1811/3463 |
| 2023 | -10.34% 1291/2656 |
7.30% 586/2280 |
-6.09% 1588/2385 |
-8.30% 1690/2515 |
-2.97% 565/2655 |
| 2022 | -25.85% 1352/2207 |
-21.85% 1659/1919 |
4.40% 1018/2016 |
-13.98% 1005/2113 |
5.65% 453/2208 |
| 2021 | 0.17% 725/1822 |
-6.34% 996/1255 |
20.38% 146/1330 |
-13.67% 1354/1466 |
2.91% 499/1822 |
| 2020 | 62.68% 113/1250 |
5.42% 55/1028 |
30.26% 61/1067 |
7.07% 803/1164 |
10.65% 587/1184 |
| 2019 | - - |
- - |
- - |
8.90% 59/850 |
10.28% 149/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏创业板价值ETF VS. 长安沪深300非周期A(740101) |